Navigation Links
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Date:12/30/2011

AMSTERDAM, December 30, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

Under the terms of the transaction, AMT has agreed to issue 7,352,938 new shares at a price of € 0.34 per share, being the closing price on December 29, 2011, when the shares were placed. The proceeds of this issue will provide additional flexibility to further explore its strategic options to secure the financial stability of the Company. The proceeds do not eliminate the Company's negative equity position, which will continue after completion of the equity raising, which is expected to take place on or around January 4, 2012, and the Company's financial prospects remain as described in the announcement of December 15, 2011.

As a result of the private placement, the Company's issued share capital will amount to 31,051,454 shares.

Pursuant to the Financial Supervision Act (Wet op het financieel toezicht) there is no obligation to publish a prospectus approved by the Netherlands Authority for the Financial Markets (Autoriteit Financiele Markten) in relation to the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam. The Netherlands Authority for the Financial Markets does not supervise the equity raising or the admission of the new shares to trading on NYSE Euronext in Amsterdam.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the del
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
5. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
7. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... global consumption of squalene / squalane is expected to be ... that finds applications in various end user industries such as ... applications like high grade lubrication, and fiber coating additives. ... is regionally segregated. Sophim ( France ), Amyris ... Japan ), SeaDragon Marine Oils Ltd. ( New ...
(Date:9/17/2014)... 2014 Shimadzu Scientific Instruments ... (2D-LC), which offers a powerful separation method ... system provides a new level of knowledge ... beneficial to scientists analyzing pharmaceutical impurities, proteins, ... , Comprehensive 2D-LC combines two independent separation ...
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing ... Goodwin to its Board of Directors as a director and Audit ... President and CEO of Keren Pharmaceutical, a company focused on exploiting ...
... , , , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... most notably Novartis,s Diovan -- the hypertension drug market will ... the market will decrease by 1.4 percent annually and thereafter ...
... , GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... Phase 2 Small Business Innovation and Research (SBIR) grant from the ... Institutes of Health (NIH) to support the development of GenVec,s vector ... http://www.newscom.com/cgi-bin/prnh/ 2 0081205/DC50112LOGO ) , , ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents 2GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... real cost of Herceptin is borne by other patients whose ... doctors in this week’s BMJ. , New guidance from the ... (Herceptin) in early breast cancer, but it provides no extra ... to release this extra money. This leaves medical staff with ...
... larvae, warmed in a toasty lab chamber, are giving Cornell ... see how genes are expressed in living tissue. , Using ... Watt W. Webb, researchers have for the first time been ... activate their genes to synthesize key proteins in fruit fly ...
... protein converts chemical energy to mechanical force, thus powering ... structural model by University of North Carolina at Chapel ... a scientific mystery: how the protein dynein fuels itself ... include mitosis, or cell division into identical cells. ...
Cached Biology News:Other patients bear the real cost of Herceptin 2Researchers use multiphoton microscopy to watch chromosomes in action 2Researchers use multiphoton microscopy to watch chromosomes in action 3UNC scientists solve mystery of how largest cellular motor protein powers movement 2
Template and primers for preparation of internal control spots...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
GOAT ANTI FRK...
Biology Products: